Praziquantel Nanoparticle Formulation for the Treatment of Schistosomiasis
Ana C. Mengarda, Bruno Iles, Vinícius C. Rodrigues, Ana Luiza Lima, Victória Paz Machado, Walberson S. Reatgui, Patrícia Bento da Silva, Marina A. Radichi, Taís C. Silva, F. S. Teixeira, M. C. Salvadori, Marina M. Simões, Karen L. R. Paiva, César Koppe Grisólia, Maria Luiza Fascineli, S.W. da Silva, Marcílio Cunha‐Filho, Sônia Nair Báo, João Paulo Figueiró Longo, Josué de Moraes
Abstract
High Resolution Image Download MS PowerPoint Slide Schistosomiasis, a parasitic disease affecting around 250 million people globally, primarily children, necessitates the urgent development of pediatric praziquantel formulations, as outlined in the WHO neglected tropical diseases roadmap 2021–2030. We developed a low-cost PZQ nanoformulation utilizing a self-nanoemulsified delivery system (SNEDDS-PZQ). Physicochemical characterization confirms its hydrodynamic size and suitability for semi-industrial pilot batch production. Toxicity studies across multiple models demonstrate its safety profile. In vivo studies in schistosomiasis animal models reveal significant parasite load reduction (over 95%) with a single oral dose of 200 and 400 mg/kg of SNEDDS-PZQ, surpassing free praziquantel efficacy. Pharmacokinetic analyses demonstrate increased PZQ blood levels postadministration of SNEDDS-PZQ. Our findings highlight the promise of this innovative approach in pediatric schistosomiasis treatment by using this nanotechnology as a delivery system, offering potential for widespread application.